P024 Comparison of CCP2 and CCP3 assays in a large cohort of established rheumatoid arthritis and controls

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 1; p. A24
• Main Authors: Malher, M, Bentow, C, Albesa, R, Cesana, L, Martinez-Prat, L, Roux-Lombard, P, Nissen, MJ, Lamacchia, C, Gabay, C
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2018
• Subjects: Ankylosing spondylitis; Citrulline; Enzyme-linked immunosorbent assay; Epitopes; Filaggrin; Immunoglobulin G; Immunoglobulin M; Immunoreactivity; Psoriatic arthritis; Rheumatic diseases; Rheumatoid arthritis; Rheumatoid factor; Spondylitis; United States > US
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-EWRR2018.49

IntroductionRheumatoid Factor (RF) and anti-citrullinated protein antibodies (ACPA) are important serological marker in the diagnosis of rheumatoid arthritis (RA) and are part of the classification criteria. ACPA are generally detected using anti-cyclic citrullinated peptide (CCP) antibody assays. The first generation of the CCP test uses a peptide derived from the filaggrin protein as the antigen, whereas, the second and third generation CCP (CCP2, CCP3) are based on peptides specifically designed and optimised (mimotypes) to detect ACPA, thereby enhancing the immunoreactivity of the citrulline-containing epitope.ObjectivesThe goal was to compare the performance of CCP2 and CCP3 assays.Methods1655 samples including 968 RA patients and 687 controls (450 ankylosing spondylitis (AS) and 237 psoriatic arthritis (PsA) patients), all derived from the Swiss Clinical Quality Management in Rheumatic Diseases Foundation (SCQM) were included. ACPA were determined by CCP2 ELISA (Eurodiagnostica, Sweden), CCP3 ELISA (QUANTA Lite CCP3 IgG) and CCP3 CIA (QUANTA Flash CCP3 IgG) (both Inova Diagnostics, US). RF IgM was measured by ELISA (QUANTA Lite RF IgM, Inova Diagnostics, US).ResultsThe CCP2 ELISA showed a high sensitivity (71.1%) and a moderately high specificity (86.9%) with a corresponding Odds ratio (OR) of 16.3 (95% CI: 12.5 to 21.1). The two CCP3 assays showed lower sensitivities (61.8% for the ELISA and 61.4% for the CIA), but significantly higher specificities (98.4% and 98.5% respectively), resulting in much higher predictive values, with OR of 99.3 (95% CI: 54.4 to 181.2) and 107.5 (95% CI: 57.4 to 201.5), respectively. When compared at the same specificity (95%), the sensitivities were 61.3% for the CCP2 ELISA, 68.1% for the CCP3 ELISA and 66.1% for the CCP3 CIA. When multi-parametric analyses were performed by combining ACPA with RF IgM, combining different markers resulted in higher OR than the individual markers. The combination of CCP3 and RF IgM resulted in a higher OR (OR=187.0, 510/1655) than the combination of CCP2 with RF IgM (OR=36.7, 565/1655). The addition of CCP2 to the combination of CCP3 and RF IgM resulted in a lower OR (OR=175.0, 494/1655).ConclusionsCCP3 showed a better overall performance than CCP2 in this cohort of RA and controls, when analysed individually as well as in combination with RF IgM.Disclosure of interestNone declared